Table 4.
Glycan | Glycan structure | Locus | Gene | SNP | Number of SNPs in the interval | Effect on transcript | eQTL in relevant tissues/tissue | pQTL; protein; tissue | Disease gene (s); disease |
---|---|---|---|---|---|---|---|---|---|
GP19 | Man9 | 19: 6,710,782–6,713,262 | C3 | rs1047286 | 2 |
Direct: rs1047286 missense coding variant, C3 protein pPro314Leu substitution Putative: C3 rs2230203 synonymous coding variant |
C8; C8; plasma | C3, C8A/B/G; increased risk of type 1 diabetes among HLA-DR4/4 carriers [41]a, macular degeneration, complement component 3 deficiency, haemolytic uraemic syndrome, complement component 8 deficiency type I/II | |
IGP24 | FA2BG2S2 | 22: 39,843,409–39,844,793 | rs5757680 | 2 | Intergenic region | MGAT3/whole blood | IL6ST (sGP130); IL-6 receptor subunit β (gp130, soluble); plasma | IL6ST; hyper-IgE recurrent infection syndrome 4b | |
IGP15 | FA2BG2 | 22: 39,739,638–39,756,985 | SYNGR1 | rs137702 | 7 | Putative: SYNGR1 intron variants (rs137702, rs137707, rs2413589, rs4821887) | MGAT3/B cells | IL6ST (sGP130); IL-6 receptor subunit β (gp130, soluble); plasma | IL6ST; hyper-IgE recurrent infection syndrome 4b |
Each locus is represented by the SNP with the strongest association in the region. Locus information is presented as ‘chromosome number: locus start – locus end’. The results are reported for GRCh Build 37. eQTL, pQTL, disease gene/disease, effect on transcript and LD were obtained using SNiPA [35], and SNPs were grouped in the same genomic interval based on LD (R2>0.5) with the top associated SNP within the interval
ars2230199 was previously associated with an increased risk of type 1 diabetes among HLA-DR4/4 carriers (R2=0.82 with rs1047286; R2=0.7 with rs2230203)
C8A/B/G, complement C8 α/β/γ chain gene; IL6ST, interleukin 6 cytokine family signal transducer gene; gp130, soluble glycoprotein 130 (synonyms: IL6ST, soluble)